anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
IM Fulvestrant 250mg given once on Day 1; Oral Placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
PURPOSE:To produce the titled novel compound resistant to hydrolysis and having excellent stability, by copolymerizing a vinyl monomer to a vinylspiropyran derivative prepared from chloromethyl-substituted salicylaldehyde by a specific process. CONSTITUTION:The chloromethyl-substituted salicylaldehyde of formula I or formula II (R<1> is H, nitro, etc.) is made to react with triphenyl phosphite, and the resultant phosphonium salt is made to react with excess formaldehyde in the presence of an alkali to obtain a vinylsalicylaldehyde derivative. The objective copolymer of formula V or Vi (M is vinyl monomer unit; m and n are positive integer) can be produced by reacting the above derivative with the quaternary iodide of formula III (R2 is H, halogen, etc.) (e.g. substituted indolium iodide) and copolymerizing the obtained vinylspiropyran derivative with a vinyl monomer.
Pandemic A(H1N1) continues its global spread, and vaccine production is a serious problem. Protection by current vaccines is limited by the mutational differences that rapidly accumulate in the circulating strains, especially in the virus surface proteins. New vaccine strategies are focusing at conserved regions of the viral internal proteins to produce T cell epitope-based vaccines. T cell responses have been shown to reduce morbidity and promote recovery in mouse models of influenza challenge. We previously reported 54 highly conserved sequences of NP, Ml and the polymerases of all human H1N1, H3N2, H1N2, and H5N1, and avian subtypes over the past 30 years. Sixty-three T cell epitopes elicited responses in HLA transgenic mice (A2, A24, B7, DR2, DR3 and DR4). These epitopes were compared to the 2007-2009 human H1N1 sequences to identify conserved and variant residues. Seventeen T cell epitopes of PB1, PB2, and M1 were selected as vaccine targets by analysis of sequence conservation and variability, functional avidity, non-identity to human peptides, clustered localization, and promiscuity to multiple HLA alleles. The vaccines composed of these epitopes, being highly conserved and temporally stable, would be useful for any avian or human influenza A virus.
Cardiac surgery with cardiopulmonary bypass (CPB) is associated with ischemia-reperfusion (I-R) injury. Acute myocardial injury after cardiac surgery is associated with increased mortality and morbidity. In 1993, reported that brief circumflex artery occlusion reduces myocardial infarct size induced by a definitive occlusion of the left anterior descending artery, a phenomenon which has been named remote ischemic preconditioning (RIPC). This approach confers resistance to subsequent ischemic episodes in remote organs, possibly by transferring protective mediators through humoral, neuronal, and systemic mechanisms, however the mechanisms involved are not yet fully known. A recent study has found that cardioprotection induced by RIPC the mitochondria appear to be an important subcellular effector organelle. It has been reported that RIPC could be a potential protective approach for perioperative complications. Therefore, the effects on myocardial injury and clinical outcome in patients undergoing on-pump cardiac surgery (OPCS) are inconclusive. In the present study, we conducted a randomized clinical trial on patients undergoing OPCS by application of remote ischemic postconditioning (RIP), an alternative to remote ischemic preconditioning. RIP can be applied in different clinical situations, medical or surgical, when reperfusion is initiated and associated to acidosis, nitric oxide formation, mitochondrial permeability transition pore inhibition and reactive oxygen species generation. In the present study we have opted for remote postconditioning because we speculate a possible losses of plasmatic effectors during CPB procedures using polyvinylchloride (PVC) tubing. Since, when blood is exposed to the PVC surface the plasma proteins may be adsorbed. Also to minimize the bleeding or hemodilution effects on the potential protective plasmatic effectors levels during CPB.

Tissue exposure to low O2 concentration starts a hypoxic response of the hypoxia-inducible factor 1 (HIF-1), a transcription factor heterodimer, consisting of an O2 regulated HIF-1α subunit and a constitutively expressed HIF-1β subunit that binds to the consensus sequence 5'-RCGTG-3', which is present near HIF-1-regulated genes. HIF-1α protein stability is upregulated in response to hypoxia. HIF-1α protein stability is negatively regulated by O2-dependent prolyl hydroxylation and is degraded under normoxia by prolyl hydroxylase. HIF-1α plays a critical role in the mammalian cells activating genes associate with angiogenesis, ischemia, energy metabolism and cell cycle.

The aim of this study carried out in patients undergoing OPCS was the determination of the time course of HIF-1α plasma levels in response to RIP and the possible correlation between aortic cross-clamping time and HIF-1α plasma levels in both groups. HIF-1α role in remote ischemic conditioning (pre or post) is very little known. Therefore, we tested the hypothesis that RIP induces cardiac protection after OPCS and that this is associated to an increase of HIF-1α plasma levels.
The invention belongs to the research of the application field of FUNDC1, and particularly discloses an application of FUNDC1 in preparing a medicament for preventing and treating vascular diseases and tumor diseases. The application of FUNDC1 inhibitor in preparing medicine for preventing and treating tumor diseases is provided. The effective component of the medicine for preventing and treating tumor diseases comprises FUNDC1 inhibitor, preferably short peptide P. Use of VEGFR2 molecular signaling pathway inhibitor in preparation of anti-tumor angiogenesis medicine. VEGFR2 molecular signaling pathway inhibiting medicine contains FUNDC1 inhibitor, preferably short peptide P as effective component. Application of FUNDC1 in preparing medicine for promoting angiogenesis is provided. A medicine for promoting angiogenesis comprises FUNDC1 as effective component; preferably, the drug is one that promotes proliferation and/or migration of HUVEC cells. The present invention relates to FUNDC1 inhibitors, in order to prevent or treat the occurrence and development of tumors; FUNDC1 can also be widely used as a medicine for treating diseases involving endothelial cells, such as retinal angiogenesis and vascular injury.
PURPOSE: An anti-diabetic composition containing dihydroavenanthramide D is provided to suppress activation of NF-kappaB and to reduce nitric oxide generation. CONSTITUTION: A composition for preventing and treating diabetes contains dihydroavenanthramide D as an active ingredient. The diabetes is a type I diabetes. A composition is used for suppressing islet injury after transplantation of pancreas or pancreatic duct. The dihydroavenanthramide D is contained in .001-100 weight% based on total weight. The composition additionally contains a carrier, excipient and diluent. The composition is used in the form of oral administration formulation, external use formulation, and sterilization injection agent.
INTRODUCTION: There is growing evidence that the use of robotic-assisted surgery (RAS) in colorectal cancer resections is associated with improved short-term outcomes when compared to laparoscopic surgery (LS) or open surgery (OS), possibly through a reduced systemic inflammatory response (SIR). Serum C-reactive protein (CRP) is a sensitive SIR biomarker and its utility in the early identification of post-operative complications has been validated in a variety of surgical procedures. There remains a paucity of studies characterising post-operative SIR in RAS.
METHODS: Retrospective study of a prospectively collected database of consecutive patients undergoing OS, LS and RAS for left-sided and rectal cancer in a single high-volume unit. Patient and disease characteristics, post-operative CRP levels, and clinical outcomes were reviewed, and their relationships explored within binary logistic regression and propensity scores matched models.
RESULTS: A total of 1031 patients were included (483 OS, 376 LS, and 172 RAS). RAS and LS were associated with lower CRP levels across the first 4 post-operative days (p < 0.001) as well as reduced complications and length of stay compared to OS in unadjusted analyses. In binary logistic regression models, RAS was independently associated with lower CRP levels at Day 3 post-operatively (OR 0.35, 95% CI 0.21-0.59, p < 0.001) and a reduction in the rate of all complications (OR 0.39, 95% CI 0.26-0.56, p < 0.001) and major complications (OR 0.5, 95% CI 0.26-0.95, p = 0.036). Within a propensity scores matched model comparing LS versus RAS specifically, RAS was associated with lower post-operative CRP levels in the first two post-operative days, a lower proportion of patients with a CRP ≥ 150 mg/L at Day 3 (20.9% versus 30.5%, p = 0.036) and a lower rate of all complications (34.7% versus 46.7%, p = 0.033).
CONCLUSIONS: The present observational study shows that an RAS approach was associated with lower postoperative SIR, and a better postoperative complications profile.
Hemophilia A is a hereditary blood clotting disorder. It is caused by a deficiency or abnormality of the blood clotting protein factor VIII. Individuals with hemophilia A are unable to form blood clots to stop bleeding and are at risk for experiencing serious and life-threatening bleeding episodes. The most common treatment for this disease is intravenous replacement of factor VIII. However, between 30 to 40% of individuals eventually develop inhibitors, or antibodies, to the replacement factor. In these individuals, the immune system recognizes the replacement factor as foreign and attacks it, thereby countering any potential benefits of the treatment. Some individuals with severe hemophilia A may undergo immune tolerance therapy (ITT), in which they receive replacement factor on a regular basis as a way for the body to adjust to the factor and stop inhibitor production. This treatment, however, is not always effective for everyone. Preliminary research has shown that rituximab, a medication used to treat non-Hodgkin's lymphoma, may be successful in suppressing or eliminating the inhibitors that develop. The purpose of this study is to evaluate the effectiveness of rituximab at lowering the levels of factor VIII inhibitors in individuals with severe hemophilia A.

This study will enroll individuals with severe hemophilia A. At study entry, participants will receive one intravenous dose of factor VIII. Inhibitor levels will be measured with a blood test 5 to 7 days following this procedure. If peak inhibitor level is above 5 Bethesda units (BU)/mL, 5 to 9 days later participants will begin receiving rituximab intravenously once a week for 4 weeks. Blood will be collected at each visit for laboratory testing. Two weeks following the last rituximab treatment, participants will have blood drawn for inhibitor testing; this testing will occur every 4 weeks through Week 22. If the participant's inhibitor level falls below 5 BU/mL, participants will receive a repeat dose of factor VIII, and blood will be drawn 5 to 7 days later for inhibitor testing. Follow-up visits will occur at Weeks 36, 52, and 100, and will include a physical examination, blood collection, and monitoring of bleeding events and infections. Telephone interviews will be conduced at Weeks 64, 76, and 88 to monitor bleeding events and infections.
BACKGROUND: Chronic migraine (CM) is a debilitating neurofunctional disorder primarily affecting females, characterized by central sensitization. Central sensitization refers to the enhanced response to sensory stimulation, which involves changes in neuronal excitability, synaptic plasticity, and neurotransmitter release. Environmental enrichment (EE) can increase the movement, exploration, socialization and other behaviors of mice. EE has shown promising effects in various neurological disorders, but its impact on CM and the underlying mechanism remains poorly understood. Therefore, the purpose of this study was to determine whether EE has the potential to serve as a cost-effective intervention strategy for CM.
METHODS: A mouse CM model was successfully established by repeated administration of nitroglycerin (NTG). We selected adult female mice around 8 weeks old, exposed them to EE for 2 months, and then induced the CM model. Nociceptive threshold tests were measured using Von Frey filaments and a hot plate. The expression of c-Fos, calcitonin gene-related peptide (CGRP) and inflammatory response were measured using WB and immunofluorescence to evaluate central sensitization. RNA sequencing was used to find differentially expressed genes and signaling pathways. Finally, the expression of the target differential gene was investigated.
RESULTS: Repeated administration of NTG can induce hyperalgesia in female mice and increase the expression of c-Fos and CGRP in the trigeminal nucleus caudalis (TNC). Early exposure of mice to EE reduced NTG-induced hyperalgesia in CM mice. WB and immunofluorescence revealed that EE inhibited the overexpression of c-Fos and CGRP in the TNC of CM mice and alleviated the inflammatory response of microglia activation. RNA sequencing analysis identified that several central sensitization-related signaling pathways were altered by EE. VGluT1, a key gene involved in behavior, internal stimulus response, and ion channel activity, was found to be downregulated in mice exposed to EE.
CONCLUSION: EE can significantly ameliorate hyperalgesia in the NTG-induced CM model. The mechanisms may be to modulate central sensitization by reducing the expression of CGRP, attenuating the inflammatory response, and downregulating the expression of VGluT1, etc., suggesting that EE can serve as an effective preventive strategy for CM.
Cannabidiol for use in the treatment of epilepsy, wherein the epilepsy is a treatment-resistant epilepsy (TRE), and wherein the TRE is Aicardi syndrome, is provided. Preferably the Aicardi syndrome is characterised by complex partial seizures with secondary generalisation and/or tonic seizures. Preferably the CBD is used in combination with one or more concomitant anti-epileptic drugs (AED) which may be selected from the group consisting of clobazam, levetiracetam, topiramate, stiripentol, phenobarbital, lacsamide, valproic acid, zonisamide, perampanel and fosphenytoin, wherein the dose of anti-epileptic drug/s that is/are used in combination with the CBD is reduced. Preferably the CBD is present as a highly purified extract which comprises at least 98% (w/w) CBD. Preferably the extract further comprises up to 1% CBDV (cannabidivarin) and less than 0.15% THC (tetrahydrocannabinol). Preferably the dose of CBD is from 5mg/kg/day to 25mg/kg/day.
Pegloticase at similar to and higher than the maximum recommended human dose (MRHD) on a plasma AUC basis [at intravenous (IV) doses of ≥ 0.4 mg/kg in dogs] caused cytoplasmic vacuoles in multiple organs, and edema and histiocyte infiltration in the aortic outflow tract in dogs. Organs with cytoplasmic vacuoles included the spleen, adrenal gland, liver, heart, duodenum, and jejunum. Vacuoles in the spleen, adrenal glands, and heart persisted after a 1-year recovery period at pegloticase doses (≥ 1.5 mg/kg in dogs) approximately 5 times the MRHD, but were absent at a dose similar to the MRHD. Vacuoles in the liver, duodenum, and jejunum persisted after a 3-month recovery period at a pegloticase dose (10 mg/kg in dogs) approximately 30 times the MRHD, but were absent at doses (≤ 1.5 mg/kg) approximately 5 times and similar to the MRHD. The edema and histiocyte infiltration in the aortic outflow tract was absent after recovery periods of 6 and 12 months, respectively.

Vacuoles in the spleen, liver, duodenum, and jejunum were within macrophages and most likely represented phagocytic removal of pegloticase from the circulation. However, the vacuolated cells in the heart and adrenal gland did not stain as macrophages. In the aortic outflow tract of the heart, vacuoles were in the cytoplasm of endothelial cells in the intimal lining of the aorta. In the adrenal gland, vacuoles were located within cortical cells in the zona reticularis and zona fasciculata. The clinical significance of these findings and the functional consequences are unknown.
Butalbital, aspirin and caffeine tablets are contraindicated under the following conditions: 

  1. Hypersensitivity or intolerance to aspirin, caffeine, or butalbital. 
  2. Patients with a hemorrhagic diathesis (e.g., hemophilia, hypoprothrombinemia, von Willebrand's disease, the thrombocytopenias, thrombasthenia and other ill-defined hereditary platelet dysfunctions, severe vitamin K deficiency and severe liver damage). 
  3. Patients with the syndrome of nasal polyps, angioedema and bronchospastic reactivity to aspirin or other nonsteroidal anti-inflammatory drugs. Anaphylactoid reactions have occurred in such patients. 
  4. Peptic ulcer or other serious gastrointestinal lesions. 
  5. Patients with porphyria.
Studies have demonstrated that laparoscopic surgery has numerous advantages over laparotomy. The patients who undergo laparoscopic surgery acquired fewer doses of analgesics than who undergo laparotomy. This point is also one of the advantages of the laparoscopic surgery. The fascia closure in fascial defects larger than 10 mm diameters in laparoscopic surgery is an important issue. Incisional hernias may occur after laparoscopic surgery. The surgeons prefer the techniques in fascial closure which is more safe and cause less pain. In current study, investigators aim to compare the post-operative incisional pain in two different techniques in gynecologic laparoscopic surgery; conventional versus by 'Berci Fascial Closure'.
Hydroxypropyl cellulose is a physiologically inert substance. In a study of rats fed hydroxypropyl cellulose or unmodified cellulose at levels up to 5% of their diet, it was found that the two were biologically equivalent in that neither was metabolized.

Studies conducted in rats fed 14C-labeled hydroxypropyl cellulose demonstrated that when orally administered, hydroxypropyl cellulose is not absorbed from the gastrointestinal tract and is quantitatively excreted in the feces. 

Dissolution studies in rabbits showed that hydroxypropyl cellulose inserts became softer within 1 hour after they were placed in the conjunctival sac. Most of the inserts dissolved completely in 14 to 18 hours; with a single exception, all had disappeared by 24 hours after insertion. Similar dissolution of the inserts was observed during prolonged administration (up to 54 weeks).
OBJECTIVE: As part of the National Disease Surveillance Program for Taiwanese Aquaculture, we investigated the causative agent of disease outbreaks in farmed Chicken Grunts Parapristipoma trilineatum.
METHODS: In this study, outbreak cases on two separate farms were noticed in coastal Pingtung County, Taiwan. In total, 50 juvenile fish showing clinical signs (such as emaciation and erratic swimming behavior) and broodstock (two females and two males) from both farms were collected to perform gross lesion assessment, histopathological examination, and molecular identification of the pathogen.
RESULT: Clinical symptoms were infected fish exhibited erratic swimming behavior, such as whirling and floating on the surface of the water. In the following months, cumulative mortality had reached 19% and 24%, respectively. The gross lesions in the infected fish included white oval cysts in the muscle, serosa of the internal organs, sclera of the eyes, and cerebral meninges. After conducting a wet mount examination of cysts using a light microscope, we observed a significant quantity of spores with morphological characteristics, suggesting their affiliation with the Myxosporea group. The spores were semiquadrate, with four tiny suture notches at the periphery; the mean spore length was 7.3 μm (SD = 0.5), and the mean spore width was 8.2 μm (SD = 0.6). The mean length and width of the pyriform polar capsules (nematocysts) were 3.6 μm (SD = 0.5) and 2.2 μm (SD = 0.5), respectively. The 18S and 28S ribosomal RNA sequences of these specimens were identical to those of Kudoa lutjanus.
CONCLUSION: As this was the first time an outbreak of K. lutjanus in Chicken Grunts was confirmed, its reappearance with substantial mortality should serve as a warning to the aquaculture industry.
PURPOSE: To obtain a treating agent containing one of specific compounds including new compounds as an active substance, exhibiting excellent stimulating effect on hematopoietic stem cells and capable of treating hematopoietic diseases such as hematopoietic cell disorder by administering the agent to a living body in an effective amount for the control or stimulation of hematopoiesis. CONSTITUTION: This treating agent contains at least one compound selected from compounds expressed by the formula [R1 is phenyl, a 1-16C alkyl, a 6-12C (crosslinked) cycloalkyl, cycloalkyldienyl, styryl, N-oxypyridinyl, etc.; X and Y are each O or S; R3 is H, a 1-4C alkyl or a 2-5C alkoxyalkyl; R4 is H or a 1-4C alkyl; (n) is 0 or 1; R2 is H, a 1-6C alkyl, phenyl, a 6-12C (crosslinked) cycloalkyl, etc.] including new compounds, e.g. 1-(2,6-difluorobenzoyl)-3-(4- chlorophenyl) urea as active substance. The active substance is compounded with a support and supplementary agents, formulated into tablets, pills, suppositories, etc., and administered perorally or intrarectally in such a dosage form.
People living with obesity frequently have low self-esteem and a negative body image. Their relationship with their body is painful, which can lead them to dissociate themselves from it. This detachment is not conducive to lasting behavioural change. The "Awakening the Senses" programme offered to a group of patients at the Therapeutic Patient Education Unit combines aspects of cognitive behavioural therapy, mindfulness and art therapy. Its aim is to help patients reconnect with their bodies through sensory and creative experiences. This article presents the programme, the clinical observations made and the results of the various evaluations carried out.
Assessment of minimal residual disease (MRD) is the most powerful predictor of outcome in B-type acute lymphoblastic leukemia (B-ALL). MRD, defined as the presence of leukemic cells in the blood or bone marrow, is used for the evaluation of therapy efficacy. We report on a microfluidic-based MRD (MF-MRD) assay that allows for frequent evaluation of blood for the presence of circulating leukemia cells (CLCs). The microfluidic chip affinity selects B-lineage cells, including CLCs using anti-CD19 antibodies poised on the wall of the microfluidic chip. Affinity-selected cells are released from the capture surface and can be subjected to immunophenotyping to enumerate the CLCs, perform fluorescence in situ hybridization (FISH), and/or molecular analysis of the CLCs' mRNA/gDNA. During longitudinal testing of 20 patients throughout induction and consolidation therapy, the MF-MRD performed 116 tests, while only 41 were completed with multiparameter flow cytometry (MFC-MRD) using a bone marrow aspirate, as standard-of-care. Overall, 57% MF-MRD tests were MRD(+) as defined by CLC numbers exceeding a threshold of 5 × 10-4%, which was determined to be the limit of quantitation. Above a threshold of 0.01%, MFC-MRD was positive in 34% of patients. The MF offered the advantage of the opportunity for efficiently processing small volumes of blood (2 mL), which is important in the care of pediatric patients, especially infants. The minimally invasive means of blood collection are of high value when treating patients whose MRD is typically tested using an invasive bone marrow biopsy. MF-MRD detection can be useful for stratification of patients into risk groups and monitoring of patient well-being after completion of treatment for early recognition of potential impending disease recurrence.